BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34551970)

  • 1. Repurposing Vandetanib plus Everolimus for the Treatment of
    Carvalho DM; Richardson PJ; Olaciregui N; Stankunaite R; Lavarino C; Molinari V; Corley EA; Smith DP; Ruddle R; Donovan A; Pal A; Raynaud FI; Temelso S; Mackay A; Overington JP; Phelan A; Sheppard D; Mackinnon A; Zebian B; Al-Sarraj S; Merve A; Pryce J; Grill J; Hubank M; Cruz O; Morales La Madrid A; Mueller S; Carcaboso AM; Carceller F; Jones C
    Cancer Discov; 2022 Feb; 12(2):416-431. PubMed ID: 34551970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK2 inhibitors display beneficial effects in preclinical models of
    Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
    Commun Biol; 2019; 2():156. PubMed ID: 31098401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
    Broniscer A; Baker SD; Wetmore C; Pai Panandiker AS; Huang J; Davidoff AM; Onar-Thomas A; Panetta JC; Chin TK; Merchant TE; Baker JN; Kaste SC; Gajjar A; Stewart CF
    Clin Cancer Res; 2013 Jun; 19(11):3050-8. PubMed ID: 23536435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
    Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
    Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.
    Hoeman CM; Cordero FJ; Hu G; Misuraca K; Romero MM; Cardona HJ; Nazarian J; Hashizume R; McLendon R; Yu P; Procissi D; Gadd S; Becher OJ
    Nat Commun; 2019 Mar; 10(1):1023. PubMed ID: 30833574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
    Patay Z; Merchant TE; Nguyen R; Pierson CR; Onar-Thomas A; Broniscer A
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1295-1305. PubMed ID: 29165288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
    Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
    Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma.
    Thomas L; Smith N; Saunders D; Zalles M; Gulej R; Lerner M; Fung KM; Carcaboso AM; Towner RA
    J Transl Med; 2020 Nov; 18(1):424. PubMed ID: 33168005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
    Broniscer A; Baker JN; Tagen M; Onar-Thomas A; Gilbertson RJ; Davidoff AM; Pai Panandiker AS; Leung W; Chin TK; Stewart CF; Kocak M; Rowland C; Merchant TE; Kaste SC; Gajjar A
    J Clin Oncol; 2010 Nov; 28(31):4762-8. PubMed ID: 20921456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
    Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
    Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.
    Han HJ; Jain P; Resnick AC
    Bone; 2018 Apr; 109():91-100. PubMed ID: 28780023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
    Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
    PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.
    Sedlacik J; Winchell A; Kocak M; Loeffler RB; Broniscer A; Hillenbrand CM
    AJNR Am J Neuroradiol; 2013 Jul; 34(7):1450-5. PubMed ID: 23436052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
    Fortin J; Tian R; Zarrabi I; Hill G; Williams E; Sanchez-Duffhues G; Thorikay M; Ramachandran P; Siddaway R; Wong JF; Wu A; Apuzzo LN; Haight J; You-Ten A; Snow BE; Wakeham A; Goldhamer DJ; Schramek D; Bullock AN; Dijke PT; Hawkins C; Mak TW
    Cancer Cell; 2020 Mar; 37(3):308-323.e12. PubMed ID: 32142668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACVR1 mutations in DIPG: lessons learned from FOP.
    Taylor KR; Vinci M; Bullock AN; Jones C
    Cancer Res; 2014 Sep; 74(17):4565-70. PubMed ID: 25136070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.